Tonix Pharmaceuticals to develop COVID-19 skin test to measure SARS-CoV-2 exposure and T cell immunity
On Feb. 8, 2021, Tonix Pharmaceuticals announced it had received the written response from the FDA to a…
ChAdOx1 nCov-19 provided minimal protection against mild-moderate COVID-19 infection from B1351 coronavirus variant in young South African adults
On Feb. 7, 2021, Oxford University announced that an analysis, submitted as a pre-print prior to peer-review publication,…
The Wellcome Sanger Institute announced sequencing 136,383 Coronavirus genomes in the UK
On Feb. 5, 2021, the Wellcome Sanger Institute announced that to date it had sequenced 136,383 coronavirus genomes….
Oxford University vaccine effective against major B117 ﾑKentﾒ coronavirus strain circulating in the UK
On Feb. 5, 2021, Oxford University announced that a preprint of ongoing work to assess effectiveness of Oxfordﾒs…
T2 Biosystems T2SARS-CoV-2 panel proved capable of detecting the Brazil P1 variant of SARS-CoV-2 virus
On Feb. 4, 2021, T2 Biosystems announced that its T2SARS-CoV-2 Panel – a molecular diagnostic test that detects…
First-in-human clinical trial confirmed novel HIV vaccine approach
On Feb. 3, 2021, IAVI and Scripps Research announced a phase 1 clinical trial testing a novel vaccine…
NIH study of Intranasal influenza vaccine spurred strong immune response in Phase 1 study
On Feb. 3, 2021, an experimental single-dose, intranasal influenza vaccine, was safe and produced a durable immune response…
Bristol Myers and Rockefeller University announced license agreement for SARS-CoV-2 meutralizing mAb combination
On Feb. 3, 2021, Bristol-Myers and The Rockefeller University announced an agreement under which Bristol Myers Squibb was…
SARS-CoV-2 spike protein licensed by Oragenics from the NIH demonstrated protective immunity in mice
On Feb. 2, 2021, Oragenics announced that the stabilized pre-fusion spike protein CoV-2 S-2P created by the National…
VBI Vaccines announced FDA Acceptance of BLA filing for VBIﾒs 3-antigen prophylactic hepatitis B vaccine
On Feb. 2, 2021, VBI Vaccines announced that the FDA had accepted its filing of the Biologics License…
Pfizer and BioNTech published data on COVID-19 vaccine-induced antibodiesﾒ ability to neutralize SARS-CoV-2 UK strain
On Jan. 29, 2021, Pfizer and BioNTech announced that data from an in vitro study on the capability…
New COVID-19 variants fueling Africa’s second wave
On Jan. 28, 2021, The WHO announced that COVID-19 cases and deaths were surging in Africa as more…
Novavax COVID-19 vaccine demonstrated 89.3% efficacy in UK phase 3 trial
On Jan. 28, 2021, Novavax announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, had met the primary endpoint,…
Celsion filed provisional U.S. patent application for broad range of next generation DNA vaccines
On Jan. 28, 2021, Celsion announced the filing of a provisional U.S. patent application for a novel DNA-based,…
OncoSec announced first subjects dosed in phase 1 trial of CORVax12, COVID-19 vaccine candidate
On Jan. 27, 2021, OncoSec Medical announced that it had dosed several subjects in its Phase 1 clinical…
Abbott’s panbio rapid antigen test received CE Mark for asymptomatic screening and sample collection
On Jan. 26, 2021, Abbott announced it had received CE Mark for two new uses of its Panbioﾙ…
SARS-CoV-2 needs cholesterol to invade cells and form mega cells
On Jan. 25, 2021, HHMI investigators reported that cholesterol, the waxy compound better known for clogging arteries, helps…
Nirmidas Biotech received FDA Emergency Use Authorization for its COVID-19 rapid antibody fingerstick test
On Jan. 25, 2021, Nirmidas Biotech announced its second FDA Emergency Use Authorization (EUA) for their COVID-19 rapid…
OHSU study revealed SARS-CoV-2 reacted to antibodies of virus from 2003 SARS outbreak
On Jan. 25, 2021, Oregon Health & Science University (OHSU) announced a new study demonstrated that antibodies generated…
FDA approved first extended-release, injectable drug regimen for adults living with HIV
On Jan. 21, 2021, the FDA approved Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for…
A closer look at T cells revealed big differences in mild vs severe COVID-19 cases
On Jan. 21, 2021, NIH researchers announced that after people recover from infection with a virus, the immune…
Janssen announced FDA approval of CABENUVA, the first long-acting HIV treatment regimen
On Jan. 21, 2021, Janssen Pharmaceutical announced the FDA had approved CABENUVA (consisting of Janssenﾒs rilpivirine and ViiV…
XBiotech candidate True Humanﾙ COVID-19 therapy found to target highly infectious emerging strain
On Jan. 21, 2021, XBiotech announced that its COVID-19 candidate True Humanﾙ antibody therapy may also be used…
TGen-NAU study results showed COVID-19 virus triggers antibodies from previous coronavirus infections
On Jan. 19, 2021, the Northern Arizona University and TGen, an affiliate of City of Hope, announced results…
ImmunityBio announced phase I trial of COVID-19 vaccine candidate in South Africa as new variants spread
On Jan. 19, 2021, ImmunityBio announced it had received authorization from the South Africa Health Products Regulatory Authority…
Quest Diagnostics granted CDC contract to sequence COVID-19 gene variants to aid public health response
On Jan. 18, 2021, Quest Diagnostics announced that it has entered into an agreement with the Centers for…
VBI Vaccines announced publication of results from phase 4 study of prophylactic 3-ntigen HBV in vaccine
On Jan. 15, 2021, VBI Vaccines announced that results from a Phase 4 study of VBIﾒs prophylactic 3-antigen…
PerkinElmer SARS-CoV-2 RT-PCR assay received FDA EUA for asymptomatic testing
On Jan. 14, 2021, PerkinElmer announced that its PerkinElmerﾮ Coronavirus Nucleic Acid Detection Kit received Emergency Use Authorization…
Cepheid received Health Canada license for SARS-CoV-2, Flu A, Flu B and RSV combination test
On Jan. 14, 2021, Cepheid that Health Canada announced that it had issued Cepheid a medical device license…
Oxford Immunotec’s T-SPOT SARS-CoV-2 test used to measure efficacy of Valneva’s COVID-19 vaccine candidate
On Jan. 13, 2021, Oxford Immunotec announced the start of a collaboration with Valneva whereby it will perform…